Author

S. L. Latham

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

D. R. Croucher· 2 shared A. C. Chueh· 1 shared A. L. Cadell· 1 shared A. M. Ellisdon· 1 shared C. Bayly-Jones· 1 shared C. Hu· 1 shared C. L. Day· 1 shared E. V. Nguyen· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. R. Croucher

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Feed-forward stimulation of CAMK2 by the oncogenic pseudokinase PEAK1 generates a therapeutically "actionable" signalling axis in triple negative breast cancer

X. Yang, X. Ma, T. Zhao, D. R. Croucher, E. V. Nguyen, K. C. Clark, C. Hu, S. L. Latham, C. Bayly-Jones, V. C. B. Nguyen, S. Budnar, S. Shin, L. K. Nguyen, T. R. Cotton, A. C. Chueh, , R. J. Daly

This study identifies a novel feed-forward signalling axis between PEAK1 and CAMK2 in TNBC, showing that targeting CAMK2 can inhibit PEAK1-driven oncogenic processes.

bioRxiv · Feb 14, 2024Cancer Biology

A cryptic tubulin-binding domain links MEKK1 to microtubule remodelling

P. Filipcik, S. L. Latham, A. L. Cadell, C. L. Day, D. R. Croucher, P. D. Mace

This paper identifies a previously unknown TOG domain in MEKK1 that binds curved tubulin heterodimers, and shows mutations disrupting this interaction are enriched in tumors.

bioRxiv · Apr 7, 2020 · PreprintBiochemistry